Monday, December 23, 2024
HomeTagsSabatine

Sabatine

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Merck, known as MSD outside of the United States and Canada, announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616,...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics